Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0H2AM
|
|||
| Former ID |
DIB011094
|
|||
| Drug Name |
XR-3054
|
|||
| Indication | Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Terminated | [1] | |
| Company |
Xenova Group plc
|
|||
| Structure |
 |
Download2D MOL |
||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CAAX farnesyltransferase beta (FNTB) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Terpenoid backbone biosynthesis | |||
| Biosynthesis of antibiotics | ||||
| NetPath Pathway | TSH Signaling Pathway | |||
| Reactome | Inactivation, recovery and regulation of the phototransduction cascade | |||
| WikiPathways | Visual phototransduction | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | XR3054, structurally related to limonene, is a novel inhibitor of farnesyl protein transferase. Eur J Cancer. 1999 Jun;35(6):1014-9. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.